GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
    • Scientific Advisory Board
    • Reports
      • GHTM
      • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
Home / Events / GHTM Sessions | Celebrating New Research Journeys

GHTM Sessions | Celebrating New Research Journeys

November 12, 2025

📅 Date: 19 November 2025
🕒 Time: 11:00-13:00
📍 Location: ZOOM & Sala Fraga de Azevedo | IHMT-NOVA

 

As part of the “Celebrating New Research Journeys” GHTM Series of Sessions, the next GHTM session will spotlight two of our new tenure researchers — David Pires and Vítor Pimentel — who will present the projects they will be developing at GHTM.

David Pires (THOP-GHTM) will introduce his work focus on the complex interplay between humans and microbes, with a special emphasis on tuberculosis. His research seeks to identify new molecules and host targets that can boost the immune response and fight infection more effectively. By developing 3D infection models that better replicate the tuberculosis granuloma, he aims to enhance drug discovery and create therapies that act on both the pathogen and the immune system.

Vítor Pimentel (THOP-GHTM) will present his research, combining real-time genomic sequencing and machine learning to study HIV diversity and drug resistance, particularly in low- and middle-income countries. His work uses portable sequencing tools like MinION to generate insights that support clinical and public health decision-making, contributing to the WHO’s goal of ending HIV/AIDS by 2030.

This session offers a unique opportunity to learn about their innovative research directions in infectious diseases and global health.

If you are a GHTM member, you will receive the details of the session by e-mail. If you are not a GHTM member and would like to join the session, please contact us at ghtm-info@ihmt.unl.pt.

Share this:

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to print (Opens in new window) Print

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2026 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

 

Loading Comments...
 

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.